

DOTA Zoledronate Biochemical | DOTA biochemical

DOTA Zoledronate

CATALOG #
AAA227980

PRODUCT SYNONYMS

DOTA Zoledronate; DCR-PHXC; DOTA biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1908409-18-6
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Nedosiran, CAS 2266591-83-5



Structure
Nedosiran, CAS 2266591-83-5

ADDITIONAL INFORMATION

Related Product Information for DOTA biochemical	DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for identifying bone metastases.
References	1. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149. 2. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098. 3. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

